Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Shares Outstanding (2016 - 2022)

Historic Shares Outstanding for Viridian Therapeutics, Inc.\DE (VRDN) over the last 8 years, with Q2 2022 value amounting to $28.5 million.

  • Viridian Therapeutics, Inc.\DE's Shares Outstanding rose 23063.49% to $28.5 million in Q2 2022 from the same period last year, while for Jun 2022 it was $28.5 million, marking a year-over-year increase of 23063.49%. This contributed to the annual value of $23.9 million for FY2021, which is 46542.76% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Shares Outstanding of $28.5 million as of Q2 2022, which was up 23063.49% from $27.2 million recorded in Q1 2022.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Shares Outstanding registered a high of $28.5 million during Q2 2022, and its lowest value of $2.1 million during Q4 2018.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Shares Outstanding had a median value of $5.7 million in 2020 and averaged $11.2 million.
  • Its Shares Outstanding has fluctuated over the past 5 years, first skyrocketed by 1304.31% in 2019, then surged by 46542.76% in 2021.
  • Viridian Therapeutics, Inc.\DE's Shares Outstanding (Quarter) stood at $2.1 million in 2018, then increased by 13.04% to $2.3 million in 2019, then surged by 82.05% to $4.2 million in 2020, then soared by 465.43% to $23.9 million in 2021, then increased by 18.98% to $28.5 million in 2022.
  • Its Shares Outstanding was $28.5 million in Q2 2022, compared to $27.2 million in Q1 2022 and $23.9 million in Q4 2021.